Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab.
Authors
Akira Ooki
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;
Akira Ooki , Sachiko Yamamoto , Hisato Kawakami , Tomoki Makino , Akihito Kawazoe , Toshiki Masuishi , Takahiro Tsushima , Motohiro Hirao , Naoki Takegawa , Kaori Hino , Satoru Iwasa , Hiroki Hara , Naoki Sumiyoshi , Daiko Matsuoka , Yohei Otake , Keisuke Yasuda , Takao Takase , Shuya Takashima , Taro Semba , Takashi Oshima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04078295
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 337)
DOI
10.1200/JCO.2023.41.4_suppl.337
Abstract #
337
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Manish R. Patel
Poster
2023 ASCO Annual Meeting
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
First Author: Koichi Azuma
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Gastric cancer (GC) cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) in combination with nivolumab.
First Author: Kei Muro
Poster
2022 ASCO Annual Meeting
Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
First Author: Roland Lang